Assessment of patients affected by rheumatoid arthritis eligible for biotechnological agents and evaluation of their healthcare resource utilization and related costs. Reumatismo, [S. l.], v. 73, n. 1, p. 5–14, 2021. DOI: 10.4081/reumatismo.2021.1329. Disponível em: https://www.reumatismo.org/reuma/article/view/1329. Acesso em: 7 jun. 2025.